Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven breast cancer
• * Metastatic disease OR
• * Locoregional relapse following optimal adjuvant therapy and regional treatment
• * HER-2/neu overexpression (3+ by immunohistochemistry OR gene amplification by FISH)
• Hormone receptor status:
• * Not specified
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Sex:
• Female
• Menopausal status:
• Not specified
• Performance status:
• ECOG 0-2
• Life expectancy:
• Not specified
• Hematopoietic:
• Absolute neutrophil count at least 1,500/mm3
• Platelet count at least 100,000/mm3
• Hemoglobin at least 10 g/dL
• Hepatic:
• SGOT and SGPT no greater than 3 times upper limit of normal (ULN)
• Alkaline phosphatase no greater than 2 times ULN unless documented to be arising from bone
• Bilirubin no greater than 1.5 times ULN
• Renal:
• BUN less than 1.5 times ULN
• Creatinine less than 1.5 times ULN
• Cardiovascular:
• LVEF normal by radioisotope method
• No history of congestive cardiac failure, myocardial infarction, cardiac arrhythmia, or ischemic heart disease requiring medication
• Other:
• Not pregnant or nursing
• Fertile patients must use effective contraception
• No known sensitivity to benzyl alcohol
• No other prior malignancy except adequately treated nonmelanomatous skin cancer or carcinoma in situ of the cervix
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• Biologic therapy:
• Not specified
• Chemotherapy:
• No prior doxorubicin greater than 240 mg/m2
• Endocrine therapy:
• Not specified
• Radiotherapy:
• Prior radiotherapy to left breast or chest wall allowed
• Surgery:
• Not specified